Daltroban is primarily used as a selective thromboxane A2 receptor antagonist. It plays a significant role in research related to platelet aggregation and vascular constriction. By blocking thromboxane receptors, it helps in studying conditions involving abnormal blood clotting and ischemic events. It has been investigated for its potential in reducing thrombotic events without significantly affecting bleeding time, making it useful in cardiovascular research. Additionally, Daltroban has been explored in models of organ transplantation and inflammation, where modulation of thromboxane activity is critical. Its application remains largely experimental, supporting pharmacological studies rather than clinical therapy.